[1]Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics[J]. Oncogene, 2010, 29(5):625-634.
[2]Koshiji M, To KK, Hammer S, et al. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression[J]. Mol Cell, 2005, 17(6): 793-803.
[3]Chen N, Chen X, Huang R, et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}[J]. J Biol Chem, 2009, 284(15):10004-10012.
[4]Flamant L, Notte A, Ninane N, et al. Anti-apoptotic role of HIF-1and AP-1 in paclitaxel exposed breast cancer cells under hypoxia[J]. Mol Cancer, 2010, 9: 191.
[5]Nguyen M, Marcellus RC, Roulston A, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis[J]. Proc Natl Acad Sci USA, 2007, 104(49):19512-19517.
[6]Acoca S, Cui Q, Shore GC, et al. Molecular dynamics study of small molecule inhibitors of the Bcl-2 family[J]. Proteins, 2011, 79(9):2624-2636
[7]Zhai D,Jin C,Satterthwait AC,et al.Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins[J].Cell Death Differ,2006,13(8):1419-1421.
[8]Erler J,Cawthorne C,Williams K,et al.Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance[J].Mol Cell Biol,2004,24(7):2875-2889.
[9]Adamski J, Price A, Dive C, et al. Hypoxia-induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1alpha[J]. PLoS One, 2013, 8(6):e65304.
[10]Cosse J, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression[J]. Anticancer Agents Med Chem, 2008, 8(7):790-797.
[11]Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia[J]. Med Oncol, 2001, 18(4):243-259.
[12]Vogler M,Weber K,Dinsdale D,et al.Different forms of cell death induced by putative BCL2 inhibitors[J].Cell Death Differ,2009,16(7):1030-1039. |